Bio Rad Laboratories, Inc. BIO
We take great care to ensure that the data presented and summarized in this overview for BIO-RAD LABORATORIES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BIO
View all-
First Eagle Investment Management, LLC2.52MShares$697 Million1.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.85MShares$511 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.55MShares$429 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1MShares$277 Million0.06% of portfolio
-
Veritas Asset Management LLP863KShares$239 Million2.27% of portfolio
-
Ariel Investments, LLC Chicago, IL819KShares$227 Million2.51% of portfolio
-
Earnest Partners LLC Atlanta, GA606KShares$168 Million0.69% of portfolio
-
State Street Corp Boston, MA584KShares$162 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC452KShares$125 Million0.01% of portfolio
-
First Pacific Advisors, LP Los Angeles, CA387KShares$107 Million1.52% of portfolio
Latest Institutional Activity in BIO
Top Purchases
Top Sells
About BIO
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Insider Transactions at BIO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 06
2025
|
Norman D Schwartz Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,528
-0.34%
|
$450,760
$295.43 P/Share
|
Sep 06
2025
|
Norman D Schwartz Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,455
+0.77%
|
-
|
Sep 06
2025
|
Courtney C Enloe EVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
275
-30.45%
|
$81,125
$295.43 P/Share
|
Sep 06
2025
|
Courtney C Enloe EVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
768
+45.96%
|
-
|
Sep 06
2025
|
Eva Anette Engelhardt EVP, President, CDG |
SELL
Payment of exercise price or tax liability
|
Direct |
413
-31.55%
|
$121,835
$295.43 P/Share
|
Sep 06
2025
|
Eva Anette Engelhardt EVP, President, CDG |
BUY
Exercise of conversion of derivative security
|
Direct |
1,152
+46.81%
|
-
|
Sep 06
2025
|
Schwartz Allison Director |
SELL
Payment of exercise price or tax liability
|
Direct |
33
-2.22%
|
$9,735
$295.43 P/Share
|
Sep 06
2025
|
Schwartz Allison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
92
+5.82%
|
-
|
Sep 06
2025
|
James Barry EVP, President, LSG |
SELL
Payment of exercise price or tax liability
|
Direct |
378
-23.82%
|
$111,510
$295.43 P/Share
|
Sep 06
2025
|
James Barry EVP, President, LSG |
BUY
Exercise of conversion of derivative security
|
Direct |
1,056
+39.95%
|
-
|
Sep 06
2025
|
Colleen Corey EVP, Global Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
209
-1.06%
|
$61,655
$295.43 P/Share
|
Sep 06
2025
|
Colleen Corey EVP, Global Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
576
+2.83%
|
-
|
Sep 06
2025
|
Roop Kalyan Lakkaraju EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
550
-22.98%
|
$162,250
$295.43 P/Share
|
Sep 06
2025
|
Roop Kalyan Lakkaraju EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,535
+39.08%
|
-
|
Sep 06
2025
|
Sedat Evran EVP, Global Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
277
-15.39%
|
$81,715
$295.43 P/Share
|
Sep 06
2025
|
Sedat Evran EVP, Global Supply Chain |
BUY
Exercise of conversion of derivative security
|
Direct |
864
+32.43%
|
-
|
Sep 01
2025
|
Norman D Schwartz Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,084
-0.69%
|
$915,948
$297.88 P/Share
|
Sep 01
2025
|
Norman D Schwartz Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,353
+1.41%
|
-
|
Sep 01
2025
|
Colleen Corey EVP, Global Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-2.03%
|
$118,206
$297.88 P/Share
|
Sep 01
2025
|
Colleen Corey EVP, Global Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,102
+5.33%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 24.5K shares |
---|
Payment of exercise price or tax liability | 8.29K shares |
---|---|
Open market or private sale | 3K shares |